Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):861-6.

    Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways.

    Source

    Department of Dermatology, Harvard Medical School, Boston, MA 02115, USA.

    Abstract

    The switch from a quiescent tumor to an invasive tumor is accompanied by the acquisition of angiogenic properties. This phenotypic change likely requires a change in the balance of angiogenic stimulators and angiogenic inhibitors. The nature of the angiogenic switch is not known. Here, we show that introduction of activated H-ras into immortalized endothelial cells is capable of activating the angiogenic switch. Angiogenic switching is accompanied by up-regulation of vascular endothelial growth factor and matrix metalloproteinase (MMP) bioactivity and downregulation of tissue inhibitor of MMP. Furthermore, we show that inhibition of phosphatidylinositol-3-kinase leads to partial inhibition of tumor angiogenesis, thus demonstrating that activated H-ras activates tumor angiogenesis through two distinct pathways. Finally, we show evidence for two forms of tumor dormancy.

    PMID:
    9023347
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC19604
    Free PMC Article

    Images from this publication.See all images (11)Free text

    Figure 1
    Figure 2
    Figure 3
    Figure 4
    Figure 5
    Figure 6
    Figure 7
    Figure 8
    Figure 9
    Figure 10
    Figure 11

      Supplemental Content

      Icon for HighWire Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk